ACR 2024 - Featured Industry Presentations Save

ACR24 Begins today. Many of the great presentations for this meeting come from industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Below is a collection of the industry press releases detailing the abstracts, authors and presentation times from ACR  2024.  You can search the ACR site for these abstract numbers here.

UCB - new bimekizumab research in n psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS).

•  Walsh JA, Merola JF, Ritchlin CT, et al. Bimekizumab maintained efficacy responses in patients with active psoriatic arthritis: up to 2-year results from two Phase 3 studies.  
• Mease PJ, Tillett W, de Wit M, et al. Bimekizumab-treated patients with active psoriatic arthritis showed sustained improvements in pain and fatigue: up to 2-year results from two phase 3 studies.
• Maksymowych W, Ramiro S, Poddubnyy D, et al. Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two phase 3 studies. 
• Baraliakos X, Ramiro S, Maksymowych W, et al. Minimal spinal radiographic progression in patients with radiographic axial spondyloarthritis over 2 years of bimekizumab treatment: Results from a phase 3 open-label extension study. 
• Gensler L, Marzo-Ortega H, Taieb V, et al. Achievement of remission defined by absence of objective signs of inflammation vs ASDAS ID in patients with active axial spondyloarthritis treated with bimekizumab: 52-week results from two phase 3 studies. 
• Mease P, Poddubnyy D, Bajracharya R, et al. Updated Long-term safety and tolerability of bimekizumab in patients with axial spondyloarthritis and psoriatic arthritis: pooled results from phase 2b/3 studies. 

Amgen

• A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings. Abstract #0775.   MITIGATE, the first randomized, double-blind, placebo-controlled study ever conducted in IgG4-RD, evaluated the safety and efficacy of CD19+ B-cell depletion with UPLIZNA.
• Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
  Abstract #2012, Poster Session C: Monday, Nov. 18 The AGILE trial assessed the safety, tolerability and efficacy of KRYSTEXXA administered with a shorter infusion duration in patients with uncontrolled gout receiving methotrexate as co-administration.
• Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting

Janssen

• Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren’s disease study.  These data were included in a plenary session presentation (Abstract #2527) and two posters (Abstracts #1427 and #2294) and are among the Company’s 43 oral and poster presentations

Sobi

• Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
• Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
• Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies
•     Efficacy and Safety of Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still's disease: Results from a Phase 3 Study and a Pooled Analysis of Two Prospective Trials

Takeda

• New Phase 2b study results for zasocitinib, an investigational oral selective tyrosine kinase 2 (TYK2) inhibitor, will be presented at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. (Nov. 14-19) outlining rates of remission and disease activity (LDA) after 12 weeks in patients with psoriatic arthritis compared with placebo.